• According to Transparency Market Research’s latest report on the global Alpha 1 Antitrypsin Deficiency Treatment market for the historical period 2017–2018 and forecast period 2019–2027, rising incidence & prevalence of respiratory diseases and growing awareness for alpha 1 antitrypsin (AAT) deficiency are projected to drive the global Alpha 1 Antitrypsin Deficiency Treatment market during the forecast period
  • According to the report, the global Alpha 1 Antitrypsin Deficiency Treatment market was valued at US$ 1.4 Bn in 2018 and is anticipated to grow at a CAGR of 10.1% from 2019 to 2027
new fa global alpha 1 antitrypsin deficiency treatment market

To know the scope of our report Get a Sample on Alpha 1 Antitrypsin Deficiency Treatment Market

Rising incidence and prevalence of respiratory diseases across the globe: Key Driver

  • High prevalence and rise in incidence rate of respiratory diseases across the globe is a key factor driving the global Alpha 1 Antitrypsin deficiency treatment market.
  • For instance, according the World Health Organization (WHO), every year, around 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die due to this disease worldwide.
  • Furthermore, awareness for AAT deficiency in developing regions is also fuelling the growth of global Alpha 1 Antitrypsin deficiency treatment market.
  • Moreover growing government initiatives for increasing blood and plasma products and rise in prescription of combination therapies are also contributed for the growth of global market.

Get a glimpse of the in-depth analysis through our Report Brochure

Side effects and complications related to Alpha 1 Antitrypsin Deficiency Treatment products hamper the market growth

  • Treatment of Alpha 1 Antitrypsin deficiency may cause some serious side effects such as back pain, chest pain, rhinorrhea, sinusitis which can hamper the market growth.
  • High cost of therapy and lesser diagnosis rate for the disease are also some of the factors which can adversely affect the market growth.  

Global Alpha 1 Antitrypsin Deficiency Treatment Market: North America dominated the global market

  • On the basis of region, the Alpha 1 Antitrypsin Deficiency Treatment market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
  • North America region dominated the global market owing to higher prevalence of respiratory diseases in the region, higher R&D investment funding by major companies, and better diagnosis rate for AAT deficiency.
  • However, Europe region is considered as the most lucrative market during the forecast period from 2019 to 2027. The growth is mainly ascribed to factors such as growing aging population which is more prone to respiratory diseases, growing awareness & product demand of Alpha 1 Antitrypsin Deficiency Treatment, and rising research & development for respiratory disease treatment.

Expanding operations in future? To get the perfect launch ask for a custom report 

Global Alpha 1 Antitrypsin Deficiency Treatment Market: Competitive Landscape

  • This report profiles major players in the global Alpha 1 Antitrypsin deficiency treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global Alpha 1 Antitrypsin Deficiency Treatment market is highly consolidated, with a few global players accounting for a major share in market.
  • Leading players operating in the global Alpha 1 Antitrypsin Deficiency Treatment market are
    • Grifols, S.A
    • Takeda Pharmaceutical Company Limited
    • CSL Behring
    • Kamada Pharmaceuticals
    • GlaxoSmithKline Plc.
    • AstraZeneca
    • Boehringer Ingelheim GmbH
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • LFB Biomedicaments S.A.?

Global Alpha 1 Antitrypsin Deficiency Treatment Market: Key Developments

Key players in the global Alpha 1 Antitrypsin Deficiency Treatment market are engaged in regulatory approvals, new product development, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global Alpha 1 Antitrypsin Deficiency Treatment market. A few expansion strategies adopted by players operating in the global Alpha 1 Antitrypsin Deficiency Treatment market are:

  • In September 2019, Kamada Ltd. has extended strategic supply agreement with Takeda for GLASSIA [Alpha1-Proteinase Inhibitor (Human)].  This will help company to produce GLASSIA for Takeda through 2021.
  • In April 2019, U.S. FDA has approved CSL Behring product ZEMAIRA [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-gram vial sizes in the U.S. for the treatment of Alpha 1 Antitrypsin Deficiency (Alpha 1).

The report on the global Alpha 1 Antitrypsin Deficiency Treatment market discussed individual strategies, followed by company profiles of manufacturers of Alpha 1 Antitrypsin Deficiency Treatment. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global Alpha 1 Antitrypsin Deficiency Treatment market.

TMR’s report on the global Alpha 1 Antitrypsin deficiency treatment market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global Alpha 1 Antitrypsin deficiency treatment market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global Alpha 1 Antitrypsin deficiency treatment market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion-makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global Alpha 1 Antitrypsin deficiency treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global Alpha 1 Antitrypsin deficiency treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global Alpha 1 Antitrypsin deficiency treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global Alpha 1 Antitrypsin deficiency treatment market.

The report delves into the competitive landscape of the global Alpha 1 Antitrypsin deficiency treatment market. Key players operating in the global Alpha 1 Antitrypsin deficiency treatment market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global Alpha 1 Antitrypsin Deficiency Treatment market that have been profiled in this report.

Key Questions Answered in Global Alpha 1 Antitrypsin Deficiency Treatment market Report

  • What is the scope of growth of product companies in the global Alpha 1 Antitrypsin deficiency treatment market?
  • What will be the Y-o-Y growth of the global Alpha 1 Antitrypsin Deficiency Treatment market between 2019 and 2027?
  • What is the influence of changing trends in pipeline products on the global Alpha 1 Antitrypsin deficiency treatment market?
  • Will North America continue to be the most profitable market for Alpha 1 Antitrypsin Deficiency Treatment providers?
  • Which factors are anticipated to hamper the growth of the global Alpha 1 Antitrypsin Deficiency Treatment market during the forecast period?
  • Which are the leading companies in the global Alpha 1 Antitrypsin Deficiency Treatment market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global Alpha 1 Antitrypsin deficiency treatment market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global Alpha 1 Antitrypsin deficiency treatment market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the Alpha 1 Antitrypsin deficiency treatment market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the Alpha 1 Antitrypsin deficiency treatment market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global Alpha 1 Antitrypsin deficiency treatment market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global Alpha 1 Antitrypsin deficiency treatment market more reliably and accurately.

Regional Segmentation of Alpha 1 Antitrypsin Deficiency Treatment market

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

The Global Alpha-1 Antitrypsin Deficiency Treatment Market has been segmented as follows:

by Treatment Type

  • Augmentation Therapy
    • Aralast
    • Prolastin
    • Zemaira/Respreeza
    • Glassia
  • Bronchodilator
  • Corticosteroids
  • Oxygen Therapy
  • Others

by Route of Administration

  • Parenteral
  • Inhalations
  • Oral

by End-User

  • Specialty Clinics
  • Hospitals
  • Pharmacies

by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions

    2.2. Research Methodology

3. Executive Summary: 

    3.1. Global Alpha-1 Antitrypsin Deficiency Treatment: Market Snapshot         

    3.2. Market Share Analysis by Region, 2018

4. Market Overview

    4.1. Introduction

        4.1.1. Treatment Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Alpha-1 Antitrypsin Deficiency Treatment Market: Value Chain Analysis

    5.2. Comparative Brand Analysis

    5.3. Porter’s Five Forces Analysis 

    5.4. Epidemiology: Alpha-1 Antitrypsin Deficiency

    5.5. Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market

    5.6. Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market

6. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Treatment

    6.1. Introduction 

    6.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment

    6.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Treatment, 2017-2027

        6.3.1. Augmentation Therapy

            6.3.1.1. Aralast

            6.3.1.2. Prolastin

            6.3.1.3. Zemaira/Respreeza

            6.3.1.4. Glassia

        6.3.2. Bronchodilator

        6.3.3. Corticosteroids

        6.3.4. Oxygen Therapy

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Treatment, 2019-2027

7. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by End-user, 2017-2027

    7.1. Introduction 

    7.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-User

    7.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by End-user, 2017-2027

        7.3.1. Specialty Clinics

        7.3.2. Hospitals

        7.3.3. Pharmacies 

    7.4. Market Attractiveness, by End-User, 2019-2027

8. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Route of Administration, 2017-2027

    8.1. Introduction 

    8.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration

        8.2.1. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Route of Administration , 2017-2027

        8.2.2. Parenteral

        8.2.3. Inhalation

        8.2.4. Oral

    8.3. Market Attractiveness by Route of Administration, 2019-2027

9. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Region, 2017-2027

    9.1. Global Alpha-1 Antitrypsin Deficiency Treatment Market, Regional Outlook

    9.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region

    9.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Region, 2017-2027

    9.4. Market Attractiveness Analysis, by Region, 2019-2027

10. North America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

    10.1. Market Overview

    10.2. Market Analysis, by Treatment

        10.2.1. Market Value Share Analysis, by Treatment

        10.2.2. Market Value Forecast Forecast, by Treatment, 2017-2027

            10.2.2.1. Augmentation Therapy

                10.2.2.1.1. Aralast

                10.2.2.1.2. Prolastin

                10.2.2.1.3. Zemaira/Respreeza

                10.2.2.1.4. Glassia

            10.2.2.2. Bronchodilator

            10.2.2.3. Corticosteroids

            10.2.2.4. Oxygen Therapy

            10.2.2.5. Others

    10.3. Market Value Forecast, by End-user, 2017-2027

        10.3.1. Market Value Share Analysis, by End-user

        10.3.2. Market Value Forecast Forecast, by End-user

            10.3.2.1. Specialty Clinics

            10.3.2.2. Hospitals

            10.3.2.3. Pharmacies

    10.4. Market Value Forecast, by Route of Administration, 2017-2027

        10.4.1. Market Value Share Analysis, by Route of Administration

        10.4.2. Market Value Forecast Forecast, by Route of Administration

            10.4.2.1. Parenteral

            10.4.2.2. Inhalation

            10.4.2.3. Oral

    10.5. Market Value Forecast Forecast, by Country, 2017-2027

        10.5.1. Market Value Share Analysis, by Country

        10.5.2. Market Value Forecast, by Country, 2017–2027

            10.5.2.1. U.S.

            10.5.2.2. Canada

    10.6. Market Attractiveness Analysis, 2019-2027

        10.6.1. By Treatment

        10.6.2. By End-user

        10.6.3. By Route of Administration

        10.6.4. By Country 

11. Europe Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

    11.1. Market Overview

    11.2. Market Analysis, by Treatment

        11.2.1. Market Value Share Analysis, by Treatment

        11.2.2. Market Value Forecast, by Treatment, 2017-2027

            11.2.2.1. Augmentation Therapy

                11.2.2.1.1. Aralast

                11.2.2.1.2. Prolastin

                11.2.2.1.3. Zemaira/Respreeza

                11.2.2.1.4. Glassia

            11.2.2.2. Bronchodilator

            11.2.2.3. Corticosteroids

            11.2.2.4. Oxygen Therapy

            11.2.2.5. Others

    11.3. Market Value Forecast, by End-user

        11.3.1. Market Value Share Analysis, by End-user

        11.3.2. Market Value Forecast, by End-user, 2017-2027

            11.3.2.1. Specialty Clinics

            11.3.2.2. Hospitals

            11.3.2.3. Pharmacies

    11.4. Market Value Forecast, by Route of Administration, 2017-2027

        11.4.1. Market Value Share Analysis, by Route of Administration

        11.4.2. Market Value Forecast, by Route of Administration

            11.4.2.1. Parenteral

            11.4.2.2. Inhalation

            11.4.2.3. Oral

    11.5. Market Value Forecast, by Country

        11.5.1. Market Value Share Analysis, by Country

        11.5.2. Market Value Forecast, by Country, 2017-2027

            11.5.2.1. U.K.

            11.5.2.2. Germany

            11.5.2.3. France 

            11.5.2.4. Italy

            11.5.2.5. Spain

            11.5.2.6. Rest of Europe

    11.6. Market Attractiveness Analysis, 2019-2027

        11.6.1. By Treatment

        11.6.2. By End-user

        11.6.3. By Route of Administration

        11.6.4. By Country

12. Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

    12.1. Market Overview

    12.2. Market Analysis, by Treatment

        12.2.1. Market Value Share Analysis, by Treatment

        12.2.2. Market Value Forecast, by Treatment, 2017-2027

            12.2.2.1. Augmentation Therapy

                12.2.2.1.1. Aralast

                12.2.2.1.2. Prolastin

                12.2.2.1.3. Zemaira/Respreeza

                12.2.2.1.4. Glassia

            12.2.2.2. Bronchodilator

            12.2.2.3. Corticosteroids

            12.2.2.4. Oxygen Therapy

            12.2.2.5. Others

    12.3. Market Value Forecast, by End-user

        12.3.1. Market Value Share Analysis, by End-user

        12.3.2. Market Value Forecast, by End-user, 2017-2027

            12.3.2.1. Specialty Clinics

            12.3.2.2. Hospitals

            12.3.2.3. Pharmacies

    12.4. Market Value Forecast, by Route of Administration

        12.4.1. Market Value Share Analysis, by Route of Administration

        12.4.2. Market Value Forecast, by Route of Administration, 2017-2027

            12.4.2.1. Parenteral

            12.4.2.2. Inhalation

            12.4.2.3. Oral

    12.5. Market Value Forecast, by Country, 2017-2027

        12.5.1. Market Value Share Analysis, by Country

        12.5.2. Market Value Forecast, by Country, 2017-2027

            12.5.2.1. China

            12.5.2.2. Japan

            12.5.2.3. India

            12.5.2.4. Australia & New Zealand

            12.5.2.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis, 2019-2027

        12.6.1. By Treatment

        12.6.2. By End-user

        12.6.3. By Route of Administration

        12.6.4. By Country

13. Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

    13.1. Market Overview

    13.2. Market Analysis, by Treatment

        13.2.1. Market Value Share Analysis, by Treatment

        13.2.2. Market Value Forecast, by Treatment, 2017-2027

            13.2.2.1. Augmentation Therapy

                13.2.2.1.1. Aralast

                13.2.2.1.2. Prolastin

                13.2.2.1.3. Zemaira/Respreeza

                13.2.2.1.4. Glassia

            13.2.2.2. Bronchodilator

            13.2.2.3. Corticosteroids

            13.2.2.4. Oxygen Therapy

            13.2.2.5. Others

    13.3. Market Value Forecast, by End-user, 2017-2027

        13.3.1. Market Value Share Analysis, by End-user

        13.3.2. Market Value Forecast, by End-user, 2017-2027

            13.3.2.1. Specialty Clinics

            13.3.2.2. Hospitals

            13.3.2.3. Pharmacies

    13.4. Market Value Forecast, by Route of Administration

        13.4.1. Market Value Share Analysis, by Route of Administration

        13.4.2. Market Value Forecast, by Route of Administration, 2017-2027

            13.4.2.1. Parenteral

            13.4.2.2. Inhalation

            13.4.2.3. Oral

    13.5. Market Value Forecast, by Country

        13.5.1. Market Value Share Analysis, by Country

        13.5.2. Market Value Forecast, by Country, 2017-2027

            13.5.2.1. Brazil

            13.5.2.2. Mexico

            13.5.2.3. Rest of LATAM

    13.6. Market Attractiveness Analysis, 2019-2027

        13.6.1. By Treatment

        13.6.2. By End-user

        13.6.3. By Route of Administration

        13.6.4. By Country

14. Middle East and Africa Alpha-1 Antitrypsin Deficiency Treatment Market Analysis

    14.1. Market Overview

    14.2. Market Analysis, by Treatment

        14.2.1. Market Value Share Analysis, by Treatment

        14.2.2. Market Value Forecast, by Treatment, 2017-2027

            14.2.2.1. Augmentation Therapy

                14.2.2.1.1. Aralast

                14.2.2.1.2. Prolastin

                14.2.2.1.3. Zemaira/Respreeza

                14.2.2.1.4. Glassia

            14.2.2.2. Bronchodilator

            14.2.2.3. Corticosteroids

            14.2.2.4. Oxygen Therapy

            14.2.2.5. Others

    14.3. Market Value Forecast, by End-user

        14.3.1. Market Value Share Analysis, by End-user

        14.3.2. Market Value Forecast, by End-user, 2017-2027

            14.3.2.1. Specialty Clinics

            14.3.2.2. Hospitals

            14.3.2.3. Pharmacies

    14.4. Market Value Forecast, by Route of Administration

        14.4.1. Market Value Share Analysis, by Route of Administration

        14.4.2. Market Value Forecast, by Route of Administration, 2017-2027

            14.4.2.1. Parenteral

            14.4.2.2. Inhalation

            14.4.2.3. Oral

    14.5. Market Value Forecast, by Country

        14.5.1. Market Value Share Analysis, by Country

        14.5.2. Market Value Forecast, by Country, 2017-2027

            14.5.2.1. GCC Countries

            14.5.2.2. South Africa

            14.5.2.3. Rest of MEA

    14.6. Market Attractiveness Analysis, 2019-2027

        14.6.1. By Treatment

        14.6.2. By End-user

        14.6.3. By Route of Administration

        14.6.4. By Country

15. Competition Landscape

    15.1. Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2016)

    15.2. Company Profiles

        15.2.1. Grifols, S.A.

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Product Portfolio

            15.2.1.3. SWOT Analysis

            15.2.1.4. Strategic Overview

        15.2.2. AstraZeneca

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Product Portfolio

            15.2.2.3. SWOT Analysis

            15.2.2.4. Strategic Overview

        15.2.3. Teva Pharmaceutical Industries Ltd.

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Product Portfolio

            15.2.3.3. SWOT Analysis

            15.2.3.4. Strategic Overview

        15.2.4. Boehringer Ingelheim GmbH

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Product Portfolio

            15.2.4.3. SWOT Analysis

            15.2.4.4. Strategic Overview

        15.2.5. GlaxoSmithKline Plc.

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Product Portfolio

            15.2.5.3. SWOT Analysis

            15.2.5.4. Strategic Overview

        15.2.6. CSL Behring LLC

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Product Portfolio

            15.2.6.3. SWOT Analysis

            15.2.6.4. Strategic Overview

        15.2.7. Takeda Pharmaceutical Company Limited

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Product Portfolio

            15.2.7.3. SWOT Analysis

            15.2.7.4. Strategic Overview

        15.2.8. Pfizer Inc.

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Product Portfolio

            15.2.8.3. SWOT Analysis

            15.2.8.4. Strategic Overview

        15.2.9. LFB Biomedicaments S.A.

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Product Portfolio

            15.2.9.3. SWOT Analysis

            15.2.9.4. Strategic Overview

        15.2.10. Kamada Ltd

            15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.10.2. Product Portfolio

            15.2.10.3. SWOT Analysis

            15.2.10.4. Strategic Overview

List of Tables

Table 01: Comparative Analysis of Approved Alpha-1 Antitrypsin Replacement Therapy Brands

Table 02: Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market

Table 03: Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market

Table 04: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027

Table 05: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 06: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Region, 2017–2027

Table 08: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027

Table 09: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 10: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 11: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027

Table 12: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027

Table 13: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 14: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 15: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027

Table 16: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027

Table 17: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 18: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 19: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027 

Table 20: Table 17: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027

Table 21: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 22: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 23: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027

Table 24: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment Type, 2017–2027

Table 25: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027

Table 26: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027

Table 27: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027

List of Figures

Figure 01: Alpha-1 Antitrypsin Deficiency Treatment Market Snapshot

Figure 02: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast Forecast and Y-o-Y Growth (%), 2017–2027

Figure 03: Market Value Share By Treatment Type (2018)

Figure 04: Market Value Share By End-user (2018)

Figure 05: Market Value Share By Route of Administration (2018)

Figure 06: Market Value Share By Region(2018)

Figure 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 08: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Augmentation Therapy, 2017–2027

Figure 09: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bronchodilators, 2017–2027

Figure 10: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2017–2027

Figure 11: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oxygen Therapy, 2017–2027

Figure 12: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 13: Global Aralast Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 14: Global Prolastin Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 15: Global Zemaira/Respreeza Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 16: Global Glassia Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 17: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 18: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 19: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2017–2027

Figure 20: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027

Figure 21: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmacies, 2017–2027

Figure 22: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027

Figure 23: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 24: Global Parenteral Market Revenue, US$ Mn,2017-2027

Figure 25: Global Inhalation Market Revenue, US$ Mn, 2017-2027

Figure 26: Global Oral Market Revenue, US$ Mn, 2017–2027

Figure 27: Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 28: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region, 2018 and 2027

Figure 29: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Region, 2019-2027

Figure 30: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027

Figure 31: North America Market Attractiveness Analysis, by Country, 2019-2027

Figure 32: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 33: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 34: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 35: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 36: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 37: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027

Figure 38: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 39: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027

Figure 40: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country, 2019-2027

Figure 41: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 42: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 43: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 44: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 45: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 46: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027

Figure 47: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 48: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027

Figure 49: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country, 2019-2027

Figure 50: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 51: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 52: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 53: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 54: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 55: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027

Figure 56: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 57: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027

Figure 58: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country, 2019-2027

Figure 59: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 60: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 61: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 62: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 63: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 64: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027

Figure 65: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 66: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027

Figure 67: Middle East & Africa Market Attractiveness Analysis, by Country, 2019-2027

Figure 68: Middle East & Africa Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 69: Middle East & Africa Market Value Share Analysis, by End-user, 2018 and 2027

Figure 70: Middle East & Africa Market Value Share Analysis, by Route of Administration, 2018 and 2027

Figure 71: Middle East & Africa Market Value Share Analysis, by Country, 2018 and 2027

Figure 72: Middle East & Africa Market Attractiveness Analysis, by Treatment, 2019-2027

Figure 73: Middle East & Africa Market Attractiveness Analysis, by End-user, 2019-2027

Figure 73: Middle East & Africa Market Attractiveness Analysis, by Route of Administration, 2019-2027

Figure 75: Global Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2018)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Alpha 1 Antitrypsin Deficiency Treatment Market